Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102331 | 0.68 | PDPK1 (0.59) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL2126189 | 0.68 | PDPK1 (0.45) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL7275795 | 0.67 | PDPK1 (0.39) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL31556353 | 0.66 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL30632310 | 0.66 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL30534095 | 0.66 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL28154527 | 0.66 | PDPK1 (0.56) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL2935611 | 0.65 | PDPK1 (0.42) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL578376 | 0.65 | PDPK1 (0.52) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A | |
| SCHEMBL2580491 | 0.65 | PDPK1 (0.38) | PDPK1LOXL2CYP2A6HSP90AA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638568-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1638568-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | claimed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-2029153-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1638568-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1638568-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| EP-0093376-A2 | 1-Sulfo-2-azetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | PDPK1 4208/4885LOXL2 28/4885CYP2A6 315/4885 |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | PDPK1 1141/4885LOXL2 357/4885CYP2A6 21/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | PDPK1 1841/4885LOXL2 4184/4885CYP2A6 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.